Genetic variations in PTPN11 lead to a recurrent left ventricular outflow tract obstruction phenotype in childhood hypertrophic cardiomyopathy
The Journal of Thoracic and Cardiovascular Surgery · 2025
DOI: 10.1016/j.jtcvs.2024.06.012 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Thoracic and Cardiovascular Surgery, 2025. Verfasst von Shun Liu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Surgery, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Uni…. Hauptthemen laut MEDLINE: Protein Tyrosine Phosphatase, Non-Receptor Type 11, Cardiomyopathy, Hypertrophic, Phenotype, Ventricular Outflow Obstruction. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: Shenzhen Science and Technology Innovation Commission, National Science Fund for Distinguished Young Scholars, National Natural Science Foundation of China.
Abstract (Originalsprache)
OBJECTIVE: Left ventricular septal myotomy provides a favorable prognosis for children with hypertrophic obstructive cardiomyopathy (HOCM). However, some children still suffer from recurrent left ventricular outflow tract obstruction (LVOTO) after surgery. Poor prognosis exists for HOCM caused by PTPN11 mutation. Therefore, the aim of this study was to determine the clinical features of recurrent obstruction in children with HOCM caused by pathogenic mutations in the PTPN11 gene. METHODS: Fifty-six children who were diagnosed with HOCM underwent septal myectomies. Whole-exome sequencing of 49 pediatric cardiomyopathy-associated genes (including PTPN11) was performed. We performed hematoxylin-eosin, Masson, and wheat germ agglutinin staining of those tissues positive and negative for PTPN11. RESULTS: Whole-exome sequencing results showed 11 children with the PTPN11 mutation (19.6%). In long-term follow-up (median 37 months, maximum 9 years), children with the PTPN11 mutation had 6 (54.5%) recurrent LVOTOs compared with other groups (P = .015) but similar survival rates (P = .514). The mean postoperative time to recurrent obstruction was 22 ± 7 months. Children with PTPN11 mutation were 9-fold more likely to experience the risk associated with recurrent obstruction (95% confidence interval, 1.77-45.81, P < .001). Hematoxylin-eosin, Masson, and wheat germ agglutinin staining also revealed more cardiomyocyte hypertrophy in tissues with the PTPN11 mutation. CONCLUSIONS: Children with PTPN11 mutation-associated hypertrophic cardiomyopathy have a greater risk of recurrent LVOTO.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiovascular Surgery, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; State Key Laboratory of Cardiovasc…
Förderung
- Shenzhen Science and Technology Innovation Commission
- National Science Fund for Distinguished Young Scholars
- National Natural Science Foundation of China
Zitieren
APA
Liu, S., Zhao, Y., Mo, H., Hua, X., Chen, X., Wang, W., Li, Y., Yan, J., & Song, J. (2025). Genetic variations in PTPN11 lead to a recurrent left ventricular outflow tract obstruction phenotype in childhood hypertrophic cardiomyopathy. The Journal of Thoracic and Cardiovascular Surgery. https://doi.org/10.1016/j.jtcvs.2024.06.012
Vancouver
Liu S, Zhao Y, Mo H, Hua X, Chen X, Wang W, et al. Genetic variations in PTPN11 lead to a recurrent left ventricular outflow tract obstruction phenotype in childhood hypertrophic cardiomyopathy. The Journal of Thoracic and Cardiovascular Surgery. 2025. doi:10.1016/j.jtcvs.2024.06.012
BibTeX
@article{Liu2025,
author = {Liu, Shun and Zhao, Yiqi and Mo, Han and Hua, Xiumeng and Chen, Xiao and Wang, Weiteng and Li, Yijing and Yan, Jun and Song, Jiangping},
title = {Genetic variations in PTPN11 lead to a recurrent left ventricular outflow tract obstruction phenotype in childhood hypertrophic cardiomyopathy},
journal = {The Journal of Thoracic and Cardiovascular Surgery},
year = {2025},
doi = {10.1016/j.jtcvs.2024.06.012}
}
EUVIMED